In this issue:
Microbiota-derived 3-IAA influences on chemotherapy
Antibiotic receipt and survival in patients with PDAC
Temozolomide and/or capecitabine in patients with pancreatic NETs
Modified RCT for FOLFIRINOX versus gemcitabine plus nab-paclitaxel in LAPC
Comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in LAPC
Cytotoxic chemotherapy for pancreatic adenocarcinoma
Skeletal muscle mass in patients receiving gemcitabine plus nab-paclitaxel
Personalised matched targeted therapy in advanced pancreatic cancer
COVID-19 pandemic impact on pancreatic cancer treatment
Circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Please login below to download this issue (PDF)